Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib.
Laura V AshtonBarbara G AndreMaryam F AfzaliDaniel GustafsonAmy L MacNeillPublished in: Oncolytic virotherapy (2020)
Our data indicate that MYXVΔserp2 treatment benefits mice with ARMS by reducing clinical signs of disease and improving quality of life.